TORL BioTherapeutics, LLC, a clinical-stage biotechnology company involved in discovery and development of new antibody-based immunotherapies designed to improve and extend the lives of patients with cancer worldwide, has closed an oversubscribed $158 million Series B-2 financing.   The financing, led by Deep Track Capital, with new participation from global biotechnology investors including RA Capital Management, Perceptive Advisors, and Avidity Partners as well as all existing biotechnology ...